Group 1: Strategic Collaboration - Tempus AI Inc. has entered a strategic collaboration agreement with Merck & Co. to accelerate AI-driven precision medicine [1] - The partnership will utilize Tempus' extensive library of de-identified multimodal data and its advanced Lens Platform for complex analyses [2] - This collaboration aims to enhance the discovery and development of precision medicine biomarkers, particularly in oncology [2] Group 2: Financial Performance - In February, Tempus reported quarterly losses of four cents per share, aligning with consensus estimates [3] - Quarterly revenue reached $367.21 million, surpassing the Street estimate of $362.29 million and increasing from $200.68 million in the previous year [3] Group 3: Market Context - The broader market experienced a downturn, with the S&P 500 falling by 1.78% and the Nasdaq declining by 2.18%, contributing to downward pressure on Tempus shares [4] - Tempus shares are currently trading 9.8% below their 100-day simple moving average, indicating potential weakness in the longer-term trend [5] Group 4: Technical Analysis - The Relative Strength Index (RSI) is at 44.45, indicating neutral territory, while the MACD is at 0.15, below its signal line, suggesting bearish pressure [6] - The combination of neutral RSI and bearish MACD indicates mixed momentum, warranting attention for potential shifts in market sentiment [6] Group 5: Analyst Consensus - The stock carries a Buy Rating with an average price target of $74.31, with recent analyst actions reflecting varied target adjustments [7] - Tempus AI shares were down 1.56% at $52.48 at the time of publication, with key resistance at $54.00 and key support at $48.00 [7]

Core Insights - SOPHiA GENETICS reported a fourth quarter revenue of $21.7 million, a 22% increase year-over-year, and a full-year revenue of $77.3 million, up 19% year-over-year, indicating strong growth momentum [1][2] - The company experienced an IFRS net loss of $19.2 million in Q4 2025, a 27% increase from the previous year, and a full-year net loss of $79.0 million, up 26% year-over-year [1][2] - Adjusted gross margin improved to 74.2% in FY 2025, reflecting a 140 basis point increase year-over-year, despite a 40% increase in total terabytes processed by the platform [1][2] Financial Performance - Q4 2025 IFRS net loss: $19.2 million, up 27% YoY; Adjusted EBITDA loss: $9.9 million, up 9% YoY [1] - FY 2025 IFRS net loss: $79.0 million, up 26% YoY; Adjusted EBITDA loss: $41.5 million, up 3% YoY [1] - Gross margin for Q4 2025: 67.7% reported, 73.9% adjusted; FY 2025 gross margin: 67.4% reported, 74.2% adjusted [1][2] Business Highlights - The company signed 124 new core genomics customers in FY 2025, a significant increase from 92 in FY 2024, and achieved a net dollar retention rate of 115% [1][2] - New customer signings included major health systems in the U.S. expected to analyze 60,000 patients annually [1][2] - The company performed over 391,000 analyses in FY 2025, with a record 105,000 analyses in Q4 2025 [1][2] Growth Drivers - Anticipated growth in 2026 will be driven by continued execution in the U.S. market, expansion of the Liquid Biopsy application MSK-ACCESS®, and renewed momentum in the BioPharma business [1][2] - The company expects to approach adjusted EBITDA breakeven by the end of 2026 and achieve positive adjusted EBITDA in the second half of 2027 [1][2] Strategic Collaborations - A strategic collaboration was announced with MD Anderson Cancer Center to co-develop advanced multimodal oncology testing solutions [1][2] - Continued partnerships with Myriad Genetics and A.D.A.M. Innovations aim to develop MSK-ACCESS® into a regulated global companion diagnostic assay [1][2]

Core Viewpoint - SOPHiA GENETICS reported strong preliminary financial results for Q4 and full year 2025, with expectations of 20-22% revenue growth in 2026 and announced an executive transition plan promoting Ross Muken to CEO effective July 1, 2026 [1][2][3] Financial Performance - Q4 2025 revenue is projected to be at least $21 million, reflecting a year-over-year increase of approximately 20% [6] - The company performed over 105,000 analyses on SOPHiA DDM™ in Q4 2025, marking a 16% year-over-year growth [6] - Full year 2025 revenue is approximately $77 million, representing an 18% year-over-year increase [6] - The total revenue for 2026 is guided to be between $92 million and $94 million, indicating a year-over-year growth of approximately 20% to 22% [7] Executive Transition - Ross Muken, currently President and a key executive for five years, will succeed Jurgi Camblong as CEO [3][5] - Jurgi Camblong will transition to Executive Chairman, focusing on strategic initiatives and technology innovation [4][5] - Kevin Puylaert has been appointed Chief Sales Officer effective January 2026, bringing over 10 years of experience with the company [10] Growth Catalysts - The company anticipates growth drivers in 2026, including advancements in its Liquid Biopsy application MSK-ACCESS powered by SOPHiA DDM™, opportunities in the U.S. market, and a revitalized BioPharma business [2]

Core Viewpoint - Whitehawk Therapeutics Inc. announced a multi-year collaboration with Tempus AI aimed at advancing biomarker-driven research, which has influenced its stock performance despite a recent drop in after-hours trading [2]. Group 1: Collaboration Details - The partnership with Tempus AI will utilize its proprietary real-world dataset to support the development of Whitehawk's oncology pipeline [2]. - The collaboration announcement gained traction on social media, indicating potential investor interest and market engagement [2]. Group 2: Recent Earnings Performance - Whitehawk reported a loss of $0.76 per share for the second quarter, missing expectations of a $0.09 gain, and reported no revenue for the quarter, falling short of the $60 million estimate [3]. - The next earnings report is scheduled for November 15 [3]. Group 3: Stock Performance - Whitehawk's shares have gained 21.96% over the past year and risen 33.85% in the past month, although the stock is down 17.41% year-to-date in 2025 [4]. - The market capitalization of Whitehawk is $122.42 million, with shares trading between $1.39 and $3.81 over the past year and an average daily trading volume of about 118,820 shares [4]. Group 4: Stock Trend Analysis - Benzinga Edge Stock Rankings indicate that WHWK has a positive price trend across all time frames, suggesting favorable market sentiment [5].